ZIDOVUDINE

Post-LOE

zidovudine

Teva

ANDAINJECTIONINJECTABLE

Approved

May 2010

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

ZIDOVUDINE (zidovudine) by Teva is nucleoside reverse transcriptase inhibitors [moa]. Approved for human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor [epc]. First approved in 2010.

Drug data last refreshed 20h ago

Mechanism of Action

Nucleoside Reverse Transcriptase Inhibitors

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (20)

NCT00000682Phase 3Completed

A Randomized, Unblinded Trial of Zidovudine Versus ddC in the Treatment of Patients Status Post PCP Who Received Long-Term Zidovudine Therapy in Protocol ACTG 002

120 enrolled

HIV Infections

NCT00001025Phase 2Completed

Evaluation of Patients Who Have Not Had Success With Zidovudine

120 enrolled

HIV Infections

NCT00000960Phase 3Completed

The Safety and Effectiveness of Zidovudine in HIV-Infected Pregnant Women and Their Infants

1,496 enrolled

HIV InfectionsPregnancy

NCT00000731N/ACompleted

Evaluation of the Interaction Between Acetaminophen and Zidovudine

10 enrolled

HIV Infections

NCT00001063Phase 2Completed

The Effectiveness of Three Drug Combinations in HIV-Infected Patients Who Have Taken Zidovudine for More Than 12 Weeks

200 enrolled

HIV Infections

Worked on ZIDOVUDINE at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.